Cellular therapy in Chagas' disease: Potential applications in patients with chronic cardiomyopathy

Regenerative Medicine

Volumn 2, Issue 3, 2007, Pages 257-264

  Soares, Milena B P ^a,b   Garcia, Simone ^a,c   de Carvalho, Antonio Carlos Campos ^c,d   dos Santos, Ricardo Ribeiro ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b HOSPITAL SÃO RAFAEL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO NACIONAL DE CARDIOLOGIA   (Brazil)

Author keywords

Cardiomyopathy; Cellular therapy; Chaga's disease; Fibrosis; Inflammation; Stem cells

Indexed keywords

BENZNIDAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR;

ANGIOGENESIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CARDIOMEGALY; CARDIOMYOPATHY; CHAGAS DISEASE; CLINICAL TRIAL; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUSCLE DEVELOPMENT; MYOBLAST; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TERATOCARCINOMA; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT;

ANIMALS; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; CELL TRANSPLANTATION; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS;

EID: 34249827881     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.3.257     Document Type: Review

References (54)

1. World Health Report: Making a Difference. WHO, Geneva, Switzerland (1999).
2. Brener Z, Andrade ZA, Barral-Neto M: Trypanosoma Cruzi e Doença de Chagas (2nd Edition). Guanabara Koogan, Rio de Janeiro, Brazil (2000).
3. Sartori AM, Lopes MH, Benvenuti LA et al.: Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood. Am. J. Trop. Med. Hyg. 59, 784-786 (1998).
4. Galhardo MCG, Martins IA, Hasslocher-Moreno A et al.: Reactivation of Trypanosoma cruzi infection in a patient with acquired immunodeficiency syndrome. Rev. Soc. Bras. Med. Trop. 32, 291-294 (1999).
5. Dias JCP, Coura JR: Epidemiologia. In: Clínica e Terapêutica da Doença de Chagas: uma Abordagem Prática para o Clínico. Dias JCP, Coura JR (Eds). Fiocruz Publisher, Rio de Janeiro, Brazil (1997).
6. Gallagher G, Menzie S, Huang Y et al.: Regional cardiac dysfunction is associated with specific alterations in inflammatory cytokines and matrix metalloproteinases after acute myocardial infarction in sheep. Basic Res. Cardiol. 102, 63-72 (2007).
7. Janssens S, Pokreisz P, Schoonjans L et al.: Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ. Res. 94, 1256-1262 (2004).
8. Cançado JR: Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. 44(1), 29-37 (2002).
9. Garcia S, Ramos CO, Senra JF et al.: Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 49(4), 1521-1528 (2005).
10. Soares MBP, Pontes-De-Carvalho L, Ribeirodos-Santos R: The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet. Ann. Acad. Bras. Cienc. 73(4), 547-559 (2001).
11. Tarleton RL: Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31, 550-554 (2001).
12. Higuchi ML: Chronic chagasic cardiopathy: the product of a turbulent host-parasite relationship. Rev. Inst. Med. Trop. 39, 53-60 (1997).
13. Cunha-Neto E, Kalil J: Autoimmunity in Chagas' heart disease. Rev. Paul. Med. 113, 757-766 (1995).
14. Leon JS, Engman DM: Autoimmunity in Chagas heart disease. Int. J. Parasitol. 31, 555-561 (2001).
15. Pontes-de-Carvalho L, Santana CC, Soares MBP, Oliveira GG, Cunha-Neto E, Ribeiro-dos-Santos R: Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J. Autoimmun. 18(2), 131-138 (2002).
16. Scorsin M, Hagège A, Vilquin JT et al.: Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J. Thorac. Cardiovasc. Surg. 119, 1169-1175 (2000).
17. Klug MG, Soonpaa MH, Koh GY, Field LJ: Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 98, 216-224 (1996).
18. Hodgson DM, Behfar A, Zingman LV et al.: Stable benefit of embryonic stem cell therapy in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 287, H471-H479 (1994).
19. Menard C, Hagege AA, Agbulut O et al.: Transplantationm of cardiac-commited mouse embryonic stem cells to infracted sheep myocardium: a preclinical study. Lancet 366(9490), 1005-1012 (2005).
20. Laflamme MA, Gold J, Xu C et al.: Formation of human myocardium in the rat heart from human embryonic stem cells. Am. J. Pathol. 167(3), 663-671 (2005).
21. Laflamme MA, Murry CE: Regenerating the heart. Nat. Biotechnol. 23(7), 845-856 (2005).
22. Cao F, Lin S, Xie X et al.: In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113, 1005-1014 (2006).
23. Reinecke H, MacDonald GH, Hauschka SD, Murry CE: Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J. Cell Biol. 149(3), 731-740 (2000).
24. Hagege AA, Marolleau JP, Vilquin JT et al.: Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first Phase I cohort of patients. Circulation 114(Suppl. 1), I108-I113 (2006).
25. Pittenger MF, Mackay AM, Beck SC et al.: Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
26. Makino S, Fukuda K, Miyoshi S et al.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103(5), 697-705 (1999).
27. Orlic D, Kajstura J, Chimenti S et al.: Bone marrow cells regenerate infarcted myocardium. Nature 410, 701-705 (2001).
28. Wang JS, Shum-Tim D, Chedrawy E, Chiu RC: The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J. Thorac. Cardiovasc. Surg. 122, 699-705 (2001).
29. Kocher AA, Schuster MD, Szabolcs MJ et al.: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
30. Toma C, Pittenger MF, Cahill KS et al.: Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93-98 (2002).
31. Olivares EL, Ribeiro VP, Werneck de Castro JPS et al.: Bone marrow stromal cells improve cardiac performance in healed infracted rat hearts. Am. J. Physiol. Heart Circ. Physiol. 287, H464-H470 (2004).
32. Soares MBP, Lima RS, Rocha LL et al.: Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am. J. Pathol. 164(2), 441-447 (2004).
33. Rocha NN, Garcia S, Gimenez LE et al.: Characterization of cardiopulmonary function and cardiac muscarinic and adrenergic receptor density adaptation in C57BL/6 mice with chronic Trypanosoma cruzi infection. Parasitology 133, 729-737 (2006).
34. Guarita-Souza LC, Carvalho KA, Woltowicz V et al.: Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation 114(Suppl. 1), I120-I124 (2006).
35. Carvalho KA, Guarita-Souza LC, Hansen P et al.: Cell transplantation after the coculture of skeletal myoblasts and mesenchymal stem cells in the regeneration of the myocardium scar: an experimental study in rats. Transplant. Proc. 38(5), 1596-1602 (2006).
36. Vilas-Boas F, Feitosa GS, Soares MBP et al.: Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease. Arq. Bras. Cardiol. 87, 159-166 (2006).
37. Tura BR, Martino HF, Gowdak LH et al.: Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study. Trials 8, 2 (2007).
38. Gnecchi M, He H, Liang OD et al.: Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 11(4), 367-368 (2005).
39. Dawn B, Guo Y, Rezazadeh A et al.: Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ. Res. 98, 1098-1105 (2006).
40. Le Blanc K, Pittenger M: Mesenchymal stem cells: progress toward promise. Cytotherapy 7(1), 36-45 (2005).
41. Rossi MA, Souza AC: Is apoptosis a mechanism of cell death of cardiomyocytes in chronic chagasic myocarditis? Int. J. Cardiol. 68(3), 325-331 (1999).
42. + mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 78(1), 83-88 (2004).
43. Sakadia I, Terai S, Yamamoto N et al.: Transplantation of bone marrow cells reduces CC14-induced liver fibrosis in mice. Hepatology 40(6), 1304-1311 (2004).
44. Li YY, Feng YQ, Kadokami T et al.: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor a therapy. Proc. Natl Acad. Sci. USA 97(23), 12746-12751 (2000).
45. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT: Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J. Lab. Clin. Med. 143(1), 41-51 (2004).
46. Saba S, Janczewski AM, Baker LC et al.: Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am. J. Physiol. Heart Circ. Physiol. 289(4), H1456-H1467 (2005).
47. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM: Elevated concentrations of CCL2 and tumor necrosis factor-α in chagasic cardiomyopathy. Clin. Infect. Dis. 38(7), 943-950 (2004).
48. Vilas-Boas F, Ribeiro-dos-Santos R, Soares MBP et al.: Identification of regional differences in proinflammatory cytokine concentrations in chronic heart failure due to Chagas' cardiomyopathy: a key element in the comprehension of the disease. J. Am. Coll. Cardiol. 41, 155A (2003).
49. Rossi MA: Fibrosis and inflammatory cells in human chronic chagasic myocarditis: scanning electron microscopy and immunohistochemical observations. Int. J. Cardiol. 66(2), 183-194 (1998).
50. Minatoguchi, S, Takemura G, Xue-Hai C et al.: Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109, 2572-2580 (2004).
51. Harada M, Qin Y, Takano H et al.: G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat. Med. 11(3), 305-311 (2005).
52. Hasegawa H, Takano H, Iwanaga K et al.: Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J. Am. Coll. Cardiol. 47(4), 842-849 (2006).
53. Adachi Y, Imagawa J, Suzuki Y et al.: G-CSF treatment increases side population cell infiltration after myocardial infarction in mice. J. Mol. Cell. Cardiol. 36(5), 707-710 (2004).
54. Kawada H, Fujita J, Kinjo K et al.: Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104, 3581-3587 (2004).